Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA)

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Eli Lilly and Company
Information provided by (Responsible Party):
Boehringer Ingelheim
ClinicalTrials.gov Identifier:
NCT01897532
First received: July 9, 2013
Last updated: September 20, 2016
Last verified: September 2016
  Purpose
The aim of the study is to investigate the longterm impact on cardiovascular morbidity, mortality and renal function of treatment with linagliptin in a selected population of patients with T2DM and to compare outcomes against placebo, on a background of standard of care.

Condition Intervention Phase
Diabetes Mellitus, Type 2
Drug: Placebo
Drug: Linagliptin
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: CARMELINA: A Multicenter, International, Randomized, Parallel Group, Double-blind, Placebo-controlled, Cardiovascular Safety and Renal Microvascular Outcome Study With Linagliptin, 5 mg Once Daily in Patients With Type 2 Diabetes Mellitus at High Vascular Risk

Resource links provided by NLM:


Further study details as provided by Boehringer Ingelheim:

Primary Outcome Measures:
  • Time to the first occurence of any of the following adjudicated components of the primary composite endpoint: cardiovascular death, non fatal myocardial infarction, non fatal stroke and hospitalization for unstable angina pectoris [ Time Frame: 48 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Time to first occurence of any of the following adjudicated components: cardiovascular death, non fatal myocardial infarction and non fatal stroke [ Time Frame: 48 months ] [ Designated as safety issue: No ]
  • Time to first occurence of any of the following adjudicated composite renal endpoint: renal death, end stage renal disease and a sustained decrease of 50% or more in estimated glomerular filtration rate [ Time Frame: 48 months ] [ Designated as safety issue: No ]

Estimated Enrollment: 8300
Study Start Date: July 2013
Estimated Study Completion Date: January 2018
Estimated Primary Completion Date: January 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Linagliptin Drug: Linagliptin
Placebo Comparator: Placebo Drug: Placebo
placebo matching tablets

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

  1. Documented diagnosis of T2DM before visit 1(screening).
  2. Male or female patients who are drug-naïve or pre-treated with any antidiabetic background medication, excluding treatment with GLP-1 receptor agonists, DPP-4 inhibitors or SGLT-2 inhibitors if => consecutive 7 days.
  3. Stable antidiabetic background medication (unchanged daily dose) for at least 8 weeks prior to randomization. If insulin is part of the background therapy, the average daily insulin dose should not have changed by more than 10% within the 8 weeks prior to randomization compared with the daily insulin dose at randomization.
  4. HbA1c of => 6.5% and <= 10.0% at Visit 1 (screening)
  5. Age => 18 years at Visit 1(screening). For Japan only: Age => 20 years at Visit 1
  6. Body Mass Index (BMI) <= 45 kg/m2 at Visit 1 (screening)
  7. Signed and dated written informed consent by date of Visit 1(screening) in accordance with Good Clinical Practice (GCP) and local legislation prior to any study related procedure
  8. High risk of CV events defined by: 1) albuminuria (micro or macro) and previous macrovascular disease and/or 2) impaired renal function with predefined UACR

Exclusion criteria:

  1. Type 1 diabetes mellitus.
  2. Treatment (=> 7 consecutive days) with GLP-1 receptor agonists, other DPP-4 inhibitors or SGLT-2 inhibitors prior to informed consent. Note: This also includes clinical trials where these antidiabetic drugs have been provided to the patient.
  3. Active liver disease or impaired hepatic function, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase (AP) => 3 x upper limit of normal (ULN) as determined at Visit 1.
  4. eGFR <15 ml/min (severe renal impairment or ESRD, MDRD formula), as determined during screening at Visit 1 and/or the need for maintenance dialysis.
  5. Any previous (or planned within next 12 months) bariatric surgery (open or laparoscopic) or intervention (gastric sleeve).
  6. Pre-planned coronary artery re-vascularisation (PCI, CABG) or any previous PCI and/or CABG <= 2 months prior informed consent.
  7. Known hypersensitivity or allergy to the investigational products or its excipients.
  8. Any previous or current alcohol or drug abuse that would interfere with trial participation in the opinion of the investigator.
  9. Participation in another trial with an investigational drug ongoing or within 2 months prior to visit 1 (screening).
  10. Pre-menopausal women (last menstruation = 1 year prior to informed consent) who are nursing or pregnant, are of child-bearing potential and are not practicing an acceptable method of birth control (acceptable methods of birth control include tubal ligation, transdermal patch, intra uterine devices/systems (IUDs/IUSs), oral, implantable or injectable contraceptives, sexual abstinence (if allowed by local authorities), double barrier method and vasectomised partner) or do not plan to continue using acceptable method of birth control throughout the study and do not agree to submit to periodic pregnancy testing during participation in the trial.
  11. Patients considered unreliable by the investigator concerning the requirements for follow up during the study and/or compliance with study drug administration, have a life expectancy less than 5 years for non-CV causes, or have cancer other than non-melanomaskin cancer within last 3 years, or has any other condition than mentioned which in the opinion of the investigator, would not allow safe participation in the study.
  12. Acute coronary syndrome (ACS), diagnosed <= 2 months prior to visit 1 (screening).
  13. Stroke or TIA <= 3 months prior to visit 1 (screening).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01897532

  Hide Study Locations
Locations
United States, Alabama
1218.22.4107 Boehringer Ingelheim Investigational Site
Huntsville, Alabama, United States
1218.22.4172 Boehringer Ingelheim Investigational Site
Scottsboro, Alabama, United States
1218.22.4109 Boehringer Ingelheim Investigational Site
Tuscumbia, Alabama, United States
United States, Arizona
1218.22.4105 Boehringer Ingelheim Investigational Site
Glendale, Arizona, United States
1218.22.4217 Boehringer Ingelheim Investigational Site
Phoenix, Arizona, United States
United States, Arkansas
1218.22.4268 Boehringer Ingelheim Investigational Site
Harrisburg, Arkansas, United States
1218.22.4016 Boehringer Ingelheim Investigational Site
Little Rock, Arkansas, United States
1218.22.4240 Boehringer Ingelheim Investigational Site
Little Rock, Arkansas, United States
United States, California
1218.22.4011 Boehringer Ingelheim Investigational Site
Bonita, California, United States
1218.22.4255 Boehringer Ingelheim Investigational Site
Chula Vista, California, United States
1218.22.4186 Boehringer Ingelheim Investigational Site
Concord, California, United States
1218.22.4067 Boehringer Ingelheim Investigational Site
Fresno, California, United States
1218.22.4129 Boehringer Ingelheim Investigational Site
Loma Linda, California, United States
1218.22.4066 Boehringer Ingelheim Investigational Site
Long Beach, California, United States
1218.22.4156 Boehringer Ingelheim Investigational Site
Los Angeles, California, United States
1218.22.4228 Boehringer Ingelheim Investigational Site
Los Angeles, California, United States
1218.22.4154 Boehringer Ingelheim Investigational Site
Los Gatos, California, United States
1218.22.4072 Boehringer Ingelheim Investigational Site
Los Osos, California, United States
1218.22.4159 Boehringer Ingelheim Investigational Site
Modesto, California, United States
1218.22.4053 Boehringer Ingelheim Investigational Site
North Hollywood, California, United States
1218.22.4059 Boehringer Ingelheim Investigational Site
Northridge, California, United States
1218.22.4165 Boehringer Ingelheim Investigational Site
Oceanside, California, United States
1218.22.4081 Boehringer Ingelheim Investigational Site
Sacramento, California, United States
1218.22.4153 Boehringer Ingelheim Investigational Site
San Dimas, California, United States
1218.22.4005 Boehringer Ingelheim Investigational Site
San Jose, California, United States
1218.22.4171 Boehringer Ingelheim Investigational Site
Tarzana, California, United States
1218.22.4119 Boehringer Ingelheim Investigational Site
West Covina, California, United States
United States, Colorado
1218.22.4209 Boehringer Ingelheim Investigational Site
Arvada, Colorado, United States
1218.22.4142 Boehringer Ingelheim Investigational Site
Denver, Colorado, United States
1218.22.4028 Boehringer Ingelheim Investigational Site
Lakewood, Colorado, United States
United States, Florida
1218.22.4068 Boehringer Ingelheim Investigational Site
Boynton Beach, Florida, United States
1218.22.4090 Boehringer Ingelheim Investigational Site
Boynton Beach, Florida, United States
1218.22.4070 Boehringer Ingelheim Investigational Site
Bradenton, Florida, United States
1218.22.4247 Boehringer Ingelheim Investigational Site
Bradenton, Florida, United States
1218.22.4122 Boehringer Ingelheim Investigational Site
Brandon, Florida, United States
1218.22.4071 Boehringer Ingelheim Investigational Site
Brooksville, Florida, United States
1218.22.4236 Boehringer Ingelheim Investigational Site
Clearwater, Florida, United States
1218.22.4035 Boehringer Ingelheim Investigational Site
Delray Beach, Florida, United States
1218.22.4029 Boehringer Ingelheim Investigational Site
Fort Lauderdale, Florida, United States
1218.22.4064 Boehringer Ingelheim Investigational Site
Fort Lauderdale, Florida, United States
1218.22.4055 Boehringer Ingelheim Investigational Site
Hialeah, Florida, United States
1218.22.4108 Boehringer Ingelheim Investigational Site
Hialeah, Florida, United States
1218.22.4091 Boehringer Ingelheim Investigational Site
Homestead, Florida, United States
1218.22.4132 Boehringer Ingelheim Investigational Site
Jacksonville, Florida, United States
1218.22.4239 Boehringer Ingelheim Investigational Site
Jacksonville, Florida, United States
1218.22.4196 Boehringer Ingelheim Investigational Site
Lake Clarke Shores, Florida, United States
1218.22.4041 Boehringer Ingelheim Investigational Site
Lakeland, Florida, United States
1218.22.4218 Boehringer Ingelheim Investigational Site
Miami Lakes, Florida, United States
1218.22.4036 Boehringer Ingelheim Investigational Site
Miami, Florida, United States
1218.22.4045 Boehringer Ingelheim Investigational Site
Miami, Florida, United States
1218.22.4054 Boehringer Ingelheim Investigational Site
Miami, Florida, United States
1218.22.4077 Boehringer Ingelheim Investigational Site
Miami, Florida, United States
1218.22.4078 Boehringer Ingelheim Investigational Site
Miami, Florida, United States
1218.22.4085 Boehringer Ingelheim Investigational Site
Miami, Florida, United States
1218.22.4094 Boehringer Ingelheim Investigational Site
Miami, Florida, United States
1218.22.4110 Boehringer Ingelheim Investigational Site
Miami, Florida, United States
1218.22.4114 Boehringer Ingelheim Investigational Site
Miami, Florida, United States
1218.22.4115 Boehringer Ingelheim Investigational Site
Miami, Florida, United States
1218.22.4123 Boehringer Ingelheim Investigational Site
Miami, Florida, United States
1218.22.4146 Boehringer Ingelheim Investigational Site
Miami, Florida, United States
1218.22.4189 Boehringer Ingelheim Investigational Site
Miami, Florida, United States
1218.22.4206 Boehringer Ingelheim Investigational Site
Miami, Florida, United States
1218.22.4222 Boehringer Ingelheim Investigational Site
Miami, Florida, United States
1218.22.4269 Boehringer Ingelheim Investigational Site
Miami, Florida, United States
1218.22.4270 Boehringer Ingelheim Investigational Site
Miami, Florida, United States
1218.22.4097 Boehringer Ingelheim Investigational Site
North Miami Beach, Florida, United States
1218.22.4241 Boehringer Ingelheim Investigational Site
North Miami Beach, Florida, United States
1218.22.4100 Boehringer Ingelheim Investigational Site
Ocala, Florida, United States
1218.22.4130 Boehringer Ingelheim Investigational Site
Orlando, Florida, United States
1218.22.4136 Boehringer Ingelheim Investigational Site
Ormond Beach, Florida, United States
1218.22.4262 Boehringer Ingelheim Investigational Site
Plantation, Florida, United States
1218.22.4275 Boehringer Ingelheim Investigational Site
Port Charlotte, Florida, United States
1218.22.4257 Boehringer Ingelheim Investigational Site
Sarasota, Florida, United States
1218.22.4234 Boehringer Ingelheim Investigational Site
St Petersburg, Florida, United States
1218.22.4076 Boehringer Ingelheim Investigational Site
St. Petersburg, Florida, United States
1218.22.4007 Boehringer Ingelheim Investigational Site
Tampa, Florida, United States
1218.22.4061 Boehringer Ingelheim Investigational Site
West Palm Beach, Florida, United States
1218.22.4226 Boehringer Ingelheim Investigational Site
Williston, Florida, United States
United States, Georgia
1218.22.4180 Boehringer Ingelheim Investigational Site
Atlanta, Georgia, United States
1218.22.4205 Boehringer Ingelheim Investigational Site
Atlanta, Georgia, United States
1218.22.4143 Boehringer Ingelheim Investigational Site
Bainbridge, Georgia, United States
1218.22.4249 Boehringer Ingelheim Investigational Site
Cumming, Georgia, United States
1218.22.4187 Boehringer Ingelheim Investigational Site
Decatur, Georgia, United States
1218.22.4266 Boehringer Ingelheim Investigational Site
Tucker, Georgia, United States
United States, Illinois
1218.22.4179 Boehringer Ingelheim Investigational Site
Belleville, Illinois, United States
1218.22.4014 Boehringer Ingelheim Investigational Site
Chicago, Illinois, United States
1218.22.4030 Boehringer Ingelheim Investigational Site
Chicago, Illinois, United States
1218.22.4057 Boehringer Ingelheim Investigational Site
Elgin, Illinois, United States
1218.22.4161 Boehringer Ingelheim Investigational Site
Joliet, Illinois, United States
United States, Indiana
1218.22.4031 Boehringer Ingelheim Investigational Site
Avon, Indiana, United States
1218.22.4012 Boehringer Ingelheim Investigational Site
Franklin, Indiana, United States
1218.22.4032 Boehringer Ingelheim Investigational Site
Greenfield, Indiana, United States
1218.22.4003 Boehringer Ingelheim Investigational Site
Muncie, Indiana, United States
1218.22.4074 Boehringer Ingelheim Investigational Site
Valparaiso, Indiana, United States
United States, Iowa
1218.22.4176 Boehringer Ingelheim Investigational Site
Des Moines, Iowa, United States
1218.22.4237 Boehringer Ingelheim Investigational Site
Waterloo, Iowa, United States
United States, Kansas
1218.22.4102 Boehringer Ingelheim Investigational Site
Topeka, Kansas, United States
1218.22.4024 Boehringer Ingelheim Investigational Site
Wichita, Kansas, United States
1218.22.4248 Boehringer Ingelheim Investigational Site
Wichita, Kansas, United States
United States, Kentucky
1218.22.4271 Boehringer Ingelheim Investigational Site
Elizabethtown, Kentucky, United States
1218.22.4151 Boehringer Ingelheim Investigational Site
Lexington, Kentucky, United States
United States, Louisiana
1218.22.4135 Boehringer Ingelheim Investigational Site
Metairie, Louisiana, United States
1218.22.4194 Boehringer Ingelheim Investigational Site
New Orleans, Louisiana, United States
United States, Maryland
1218.22.4182 Boehringer Ingelheim Investigational Site
Baltimore, Maryland, United States
1218.22.4193 Boehringer Ingelheim Investigational Site
Baltimore, Maryland, United States
1218.22.4224 Boehringer Ingelheim Investigational Site
Baltimore, Maryland, United States
1218.22.4138 Boehringer Ingelheim Investigational Site
Salisbury, Maryland, United States
United States, Michigan
1218.22.4213 Boehringer Ingelheim Investigational Site
Alpena, Michigan, United States
1218.22.4056 Boehringer Ingelheim Investigational Site
Ann Arbor, Michigan, United States
1218.22.4001 Boehringer Ingelheim Investigational Site
Flint, Michigan, United States
1218.22.4233 Boehringer Ingelheim Investigational Site
Petoskey, Michigan, United States
1218.22.4231 Boehringer Ingelheim Investigational Site
Rochester, Michigan, United States
1218.22.4150 Boehringer Ingelheim Investigational Site
Sterling Heights, Michigan, United States
1218.22.4229 Boehringer Ingelheim Investigational Site
Waterford, Michigan, United States
United States, Minnesota
1218.22.4245 Boehringer Ingelheim Investigational Site
St. Paul, Minnesota, United States
United States, Mississippi
1218.22.4197 Boehringer Ingelheim Investigational Site
Carriere, Mississippi, United States
United States, Missouri
1218.22.4052 Boehringer Ingelheim Investigational Site
Kansas City, Missouri, United States
1218.22.4111 Boehringer Ingelheim Investigational Site
Kansas City, Missouri, United States
United States, Montana
1218.22.4092 Boehringer Ingelheim Investigational Site
Kalispell, Montana, United States
United States, Nebraska
1218.22.4188 Boehringer Ingelheim Investigational Site
North Platte, Nebraska, United States
1218.22.4075 Boehringer Ingelheim Investigational Site
Omaha, Nebraska, United States
United States, Nevada
1218.22.4264 Boehringer Ingelheim Investigational Site
Las Vegas, Nevada, United States
United States, New Jersey
1218.22.4242 Boehringer Ingelheim Investigational Site
Elizabeth, New Jersey, United States
1218.22.4025 Boehringer Ingelheim Investigational Site
Linden, New Jersey, United States
United States, New Mexico
1218.22.4033 Boehringer Ingelheim Investigational Site
Alburquerque, New Mexico, United States
United States, New York
1218.22.4093 Boehringer Ingelheim Investigational Site
Bronx, New York, United States
1218.22.4027 Boehringer Ingelheim Investigational Site
Brooklyn, New York, United States
1218.22.4215 Boehringer Ingelheim Investigational Site
Johnson City, New York, United States
1218.22.4121 Boehringer Ingelheim Investigational Site
Saratoga Springs, New York, United States
1218.22.4170 Boehringer Ingelheim Investigational Site
Syracuse, New York, United States
United States, North Carolina
1218.22.4002 Boehringer Ingelheim Investigational Site
Burlington, North Carolina, United States
1218.22.4208 Boehringer Ingelheim Investigational Site
Calabash, North Carolina, United States
1218.22.4058 Boehringer Ingelheim Investigational Site
Charlotte, North Carolina, United States
1218.22.4276 Boehringer Ingelheim Investigational Site
Gastonia, North Carolina, United States
1218.22.4043 Boehringer Ingelheim Investigational Site
Greensboro, North Carolina, United States
1218.22.4162 Boehringer Ingelheim Investigational Site
Hickory, North Carolina, United States
1218.22.4166 Boehringer Ingelheim Investigational Site
Hickory, North Carolina, United States
1218.22.4040 Boehringer Ingelheim Investigational Site
Monroe, North Carolina, United States
1218.22.4006 Boehringer Ingelheim Investigational Site
Mooresville, North Carolina, United States
1218.22.4252 Boehringer Ingelheim Investigational Site
Morehead City, North Carolina, United States
1218.22.4065 Boehringer Ingelheim Investigational Site
Morganton, North Carolina, United States
1218.22.4163 Boehringer Ingelheim Investigational Site
Salisbury, North Carolina, United States
1218.22.4098 Boehringer Ingelheim Investigational Site
Wilson, North Carolina, United States
United States, Ohio
1218.22.4207 Boehringer Ingelheim Investigational Site
Akron, Ohio, United States
1218.22.4148 Boehringer Ingelheim Investigational Site
Carlisle, Ohio, United States
1218.22.4140 Boehringer Ingelheim Investigational Site
Dayton, Ohio, United States
1218.22.4147 Boehringer Ingelheim Investigational Site
Norton, Ohio, United States
1218.22.4259 Boehringer Ingelheim Investigational Site
Springfield, Ohio, United States
1218.22.4118 Boehringer Ingelheim Investigational Site
Toledo, Ohio, United States
1218.22.4254 Boehringer Ingelheim Investigational Site
Toledo, Ohio, United States
United States, Oklahoma
1218.22.4084 Boehringer Ingelheim Investigational Site
Oklahoma City, Oklahoma, United States
1218.22.4137 Boehringer Ingelheim Investigational Site
Oklahoma City, Oklahoma, United States
United States, Oregon
1218.22.4227 Boehringer Ingelheim Investigational Site
Corvallis, Oregon, United States
United States, Pennsylvania
1218.22.4079 Boehringer Ingelheim Investigational Site
Altoona, Pennsylvania, United States
1218.22.4246 Boehringer Ingelheim Investigational Site
Altoona, Pennsylvania, United States
1218.22.4149 Boehringer Ingelheim Investigational Site
Doylestown, Pennsylvania, United States
1218.22.4250 Boehringer Ingelheim Investigational Site
Doylestown, Pennsylvania, United States
1218.22.4212 Boehringer Ingelheim Investigational Site
Jersey Shore, Pennsylvania, United States
1218.22.4265 Boehringer Ingelheim Investigational Site
Smithfield, Pennsylvania, United States
United States, South Carolina
1218.22.4019 Boehringer Ingelheim Investigational Site
Charleston, South Carolina, United States
1218.22.4088 Boehringer Ingelheim Investigational Site
Charleston, South Carolina, United States
1218.22.4190 Boehringer Ingelheim Investigational Site
Gaffney, South Carolina, United States
1218.22.4155 Boehringer Ingelheim Investigational Site
Greenville, South Carolina, United States
1218.22.4211 Boehringer Ingelheim Investigational Site
Greenville, South Carolina, United States
1218.22.4051 Boehringer Ingelheim Investigational Site
Greer, South Carolina, United States
1218.22.4062 Boehringer Ingelheim Investigational Site
Rock Hill, South Carolina, United States
United States, South Dakota
1218.22.4195 Boehringer Ingelheim Investigational Site
Rapid City, South Dakota, United States
United States, Tennessee
1218.22.4015 Boehringer Ingelheim Investigational Site
Bristol, Tennessee, United States
1218.22.4018 Boehringer Ingelheim Investigational Site
Bristol, Tennessee, United States
1218.22.4202 Boehringer Ingelheim Investigational Site
Johnson City, Tennessee, United States
United States, Texas
1218.22.4260 Boehringer Ingelheim Investigational Site
Arlington, Texas, United States
1218.22.4128 Boehringer Ingelheim Investigational Site
Austin, Texas, United States
1218.22.4160 Boehringer Ingelheim Investigational Site
Bedford, Texas, United States
1218.22.4230 Boehringer Ingelheim Investigational Site
Corpus Christi, Texas, United States
1218.22.4069 Boehringer Ingelheim Investigational Site
Dallas, Texas, United States
1218.22.4253 Boehringer Ingelheim Investigational Site
Dallas, Texas, United States
1218.22.4008 Boehringer Ingelheim Investigational Site
Houston, Texas, United States
1218.22.4037 Boehringer Ingelheim Investigational Site
Houston, Texas, United States
1218.22.4133 Boehringer Ingelheim Investigational Site
Houston, Texas, United States
1218.22.4174 Boehringer Ingelheim Investigational Site
Houston, Texas, United States
1218.22.4204 Boehringer Ingelheim Investigational Site
Houston, Texas, United States
1218.22.4244 Boehringer Ingelheim Investigational Site
Houston, Texas, United States
1218.22.4183 Boehringer Ingelheim Investigational Site
Irving, Texas, United States
1218.22.4184 Boehringer Ingelheim Investigational Site
Irving, Texas, United States
1218.22.4101 Boehringer Ingelheim Investigational Site
Katy, Texas, United States
1218.22.4203 Boehringer Ingelheim Investigational Site
New Braunfels, Texas, United States
1218.22.4235 Boehringer Ingelheim Investigational Site
Odessa, Texas, United States
1218.22.4274 Boehringer Ingelheim Investigational Site
Pearland, Texas, United States
1218.22.4017 Boehringer Ingelheim Investigational Site
San Antonio, Texas, United States
1218.22.4046 Boehringer Ingelheim Investigational Site
San Antonio, Texas, United States
1218.22.4096 Boehringer Ingelheim Investigational Site
San Antonio, Texas, United States
1218.22.4243 Boehringer Ingelheim Investigational Site
San Antonio, Texas, United States
1218.22.4099 Boehringer Ingelheim Investigational Site
Sealy, Texas, United States
1218.22.4026 Boehringer Ingelheim Investigational Site
Sugar Land, Texas, United States
1218.22.4022 Boehringer Ingelheim Investigational Site
Tomball, Texas, United States
1218.22.4010 Boehringer Ingelheim Investigational Site
Victoria, Texas, United States
United States, Utah
1218.22.4020 Boehringer Ingelheim Investigational Site
Clinton, Utah, United States
1218.22.4087 Boehringer Ingelheim Investigational Site
Draper, Utah, United States
1218.22.4126 Boehringer Ingelheim Investigational Site
Ogden, Utah, United States
1218.22.4158 Boehringer Ingelheim Investigational Site
Ogden, Utah, United States
United States, Virginia
1218.22.4095 Boehringer Ingelheim Investigational Site
Burke, Virginia, United States
1218.22.4214 Boehringer Ingelheim Investigational Site
Herndon, Virginia, United States
1218.22.4044 Boehringer Ingelheim Investigational Site
Manassas, Virginia, United States
1218.22.4134 Boehringer Ingelheim Investigational Site
Richmond, Virginia, United States
1218.22.4210 Boehringer Ingelheim Investigational Site
Richmond, Virginia, United States
1218.22.4185 Boehringer Ingelheim Investigational Site
Roanoke, Virginia, United States
1218.22.4261 Boehringer Ingelheim Investigational Site
Salem, Virginia, United States
United States, Washington
1218.22.4192 Boehringer Ingelheim Investigational Site
Port Orchard, Washington, United States
United States, Wisconsin
1218.22.4175 Boehringer Ingelheim Investigational Site
Milwaukee, Wisconsin, United States
Argentina
1218.22.1010 Boehringer Ingelheim Investigational Site
Adrogue, Argentina
1218.22.1029 Boehringer Ingelheim Investigational Site
Bahia Blanca, Argentina
1218.22.1048 Boehringer Ingelheim Investigational Site
Bahia Blanca, Argentina
1218.22.1061 Boehringer Ingelheim Investigational Site
Bahia Blanca, Argentina
1218.22.1060 Boehringer Ingelheim Investigational Site
Bahía Blanca, Argentina
1218.22.1005 Boehringer Ingelheim Investigational Site
Caba, Argentina
1218.22.1006 Boehringer Ingelheim Investigational Site
Ciudad Autonoma Buenos Aires, Argentina
1218.22.1007 Boehringer Ingelheim Investigational Site
Ciudad Autonoma Buenos Aires, Argentina
1218.22.1027 Boehringer Ingelheim Investigational Site
Ciudad Autonoma Buenos Aires, Argentina
1218.22.1044 Boehringer Ingelheim Investigational Site
Ciudad Autonoma Buenos Aires, Argentina
1218.22.1054 Boehringer Ingelheim Investigational Site
Ciudad Autonoma Buenos Aires, Argentina
1218.22.1058 Boehringer Ingelheim Investigational Site
Ciudad Autonoma Buenos Aires, Argentina
1218.22.1059 Boehringer Ingelheim Investigational Site
Ciudad Autonoma Buenos Aires, Argentina
1218.22.1043 Boehringer Ingelheim Investigational Site
Ciudad Autonoma de Bs As, Argentina
1218.22.1001 Boehringer Ingelheim Investigational Site
Cordoba, Argentina
1218.22.1012 Boehringer Ingelheim Investigational Site
Cordoba, Argentina
1218.22.1013 Boehringer Ingelheim Investigational Site
Cordoba, Argentina
1218.22.1014 Boehringer Ingelheim Investigational Site
Cordoba, Argentina
1218.22.1018 Boehringer Ingelheim Investigational Site
Cordoba, Argentina
1218.22.1026 Boehringer Ingelheim Investigational Site
Cordoba, Argentina
1218.22.1031 Boehringer Ingelheim Investigational Site
Cordoba, Argentina
1218.22.1032 Boehringer Ingelheim Investigational Site
Cordoba, Argentina
1218.22.1021 Boehringer Ingelheim Investigational Site
Corrientes, Argentina
1218.22.1019 Boehringer Ingelheim Investigational Site
Córdoba, Argentina
1218.22.1038 Boehringer Ingelheim Investigational Site
Godoy Cruz, Argentina
1218.22.1015 Boehringer Ingelheim Investigational Site
Haedo, Argentina
1218.22.1011 Boehringer Ingelheim Investigational Site
La Plata, Argentina
1218.22.1003 Boehringer Ingelheim Investigational Site
Mar del Plata, Argentina
1218.22.1053 Boehringer Ingelheim Investigational Site
Mar del Plata, Argentina
1218.22.1056 Boehringer Ingelheim Investigational Site
Mendoza, Argentina
1218.22.1049 Boehringer Ingelheim Investigational Site
Moron, Argentina
1218.22.1045 Boehringer Ingelheim Investigational Site
Parana, Argentina
1218.22.1036 Boehringer Ingelheim Investigational Site
Quilmes, Argentina
1218.22.1051 Boehringer Ingelheim Investigational Site
Quilmes, Argentina
1218.22.1002 Boehringer Ingelheim Investigational Site
Rosario, Argentina
1218.22.1004 Boehringer Ingelheim Investigational Site
Rosario, Argentina
1218.22.1008 Boehringer Ingelheim Investigational Site
Rosario, Argentina
1218.22.1009 Boehringer Ingelheim Investigational Site
Rosario, Argentina
1218.22.1020 Boehringer Ingelheim Investigational Site
Rosario, Argentina
1218.22.1022 Boehringer Ingelheim Investigational Site
Rosario, Argentina
1218.22.1039 Boehringer Ingelheim Investigational Site
Rosario, Argentina
1218.22.1040 Boehringer Ingelheim Investigational Site
Rosario, Argentina
1218.22.1041 Boehringer Ingelheim Investigational Site
Rosario, Argentina
1218.22.1046 Boehringer Ingelheim Investigational Site
Rosario, Argentina
1218.22.1055 Boehringer Ingelheim Investigational Site
Rosario, Argentina
1218.22.1034 Boehringer Ingelheim Investigational Site
Salta, Argentina
1218.22.1035 Boehringer Ingelheim Investigational Site
Salta, Argentina
1218.22.1047 Boehringer Ingelheim Investigational Site
Salta, Argentina
1218.22.1057 Boehringer Ingelheim Investigational Site
San Miguel de Tucuman, Argentina
1218.22.1037 Boehringer Ingelheim Investigational Site
San Miguel de Tucumán, Argentina
1218.22.1017 Boehringer Ingelheim Investigational Site
San Nicolas, Argentina
1218.22.1024 Boehringer Ingelheim Investigational Site
San Vicente, Argentina
1218.22.1016 Boehringer Ingelheim Investigational Site
Santa Fe, Argentina
1218.22.1028 Boehringer Ingelheim Investigational Site
Santa Fe, Argentina
1218.22.1052 Boehringer Ingelheim Investigational Site
Venado Tuerto, Argentina
1218.22.1023 Boehringer Ingelheim Investigational Site
Villa Maria, Argentina
1218.22.1025 Boehringer Ingelheim Investigational Site
Zarate, Argentina
Brazil
1218.22.1124 Boehringer Ingelheim Investigational Site
Belo Horizonte, Brazil
1218.22.1126 Boehringer Ingelheim Investigational Site
Belo Horizonte, Brazil
1218.22.1130 Boehringer Ingelheim Investigational Site
Belo Horizonte, Brazil
1218.22.1114 Boehringer Ingelheim Investigational Site
Belém, Brazil
1218.22.1103 Boehringer Ingelheim Investigational Site
Campina Grande do Sul, Brazil
1218.22.1123 Boehringer Ingelheim Investigational Site
Campinas, Brazil
1218.22.1140 Boehringer Ingelheim Investigational Site
Campinas, Brazil
1218.22.1109 Boehringer Ingelheim Investigational Site
Canoas, Brazil
1218.22.1108 Boehringer Ingelheim Investigational Site
Caxias do Sul, Brazil
1218.22.1110 Boehringer Ingelheim Investigational Site
Curitiba, Brazil
1218.22.1119 Boehringer Ingelheim Investigational Site
Curitiba, Brazil
1218.22.1120 Boehringer Ingelheim Investigational Site
Curitiba, Brazil
1218.22.1102 Boehringer Ingelheim Investigational Site
Fortaleza, Brazil
1218.22.1116 Boehringer Ingelheim Investigational Site
Fortaleza, Brazil
1218.22.1129 Boehringer Ingelheim Investigational Site
Fortaleza, Brazil
1218.22.1118 Boehringer Ingelheim Investigational Site
Goiania, Brazil
1218.22.1128 Boehringer Ingelheim Investigational Site
Lajeado, Brazil
1218.22.1135 Boehringer Ingelheim Investigational Site
Marília, Brazil
1218.22.1141 Boehringer Ingelheim Investigational Site
Niterói, Brazil
1218.22.1112 Boehringer Ingelheim Investigational Site
Passo Fundo, Brazil
1218.22.1104 Boehringer Ingelheim Investigational Site
Porto Alegre, Brazil
1218.22.1105 Boehringer Ingelheim Investigational Site
Porto Alegre, Brazil
1218.22.1106 Boehringer Ingelheim Investigational Site
Porto Alegre, Brazil
1218.22.1139 Boehringer Ingelheim Investigational Site
Porto Alegre, Brazil
1218.22.1113 Boehringer Ingelheim Investigational Site
Recife, Brazil
1218.22.1145 Boehringer Ingelheim Investigational Site
Rio de Janeiro, Brazil
1218.22.1101 Boehringer Ingelheim Investigational Site
Santa Maria, Brazil
1218.22.1127 Boehringer Ingelheim Investigational Site
Sao Jose do Rio Preto, Brazil
1218.22.1134 Boehringer Ingelheim Investigational Site
Sao Jose do Rio Preto, Brazil
1218.22.1107 Boehringer Ingelheim Investigational Site
Sao Paulo, Brazil
1218.22.1122 Boehringer Ingelheim Investigational Site
Sao Paulo, Brazil
1218.22.1138 Boehringer Ingelheim Investigational Site
São José dos Campos, Brazil
1218.22.1111 Boehringer Ingelheim Investigational Site
São Paulo, Brazil
1218.22.1115 Boehringer Ingelheim Investigational Site
São Paulo, Brazil
1218.22.1131 Boehringer Ingelheim Investigational Site
São Paulo, Brazil
1218.22.1132 Boehringer Ingelheim Investigational Site
São Paulo, Brazil
1218.22.1136 Boehringer Ingelheim Investigational Site
São Paulo, Brazil
1218.22.1142 Boehringer Ingelheim Investigational Site
São Paulo, Brazil
1218.22.1143 Boehringer Ingelheim Investigational Site
São Paulo, Brazil
1218.22.1144 Boehringer Ingelheim Investigational Site
São Paulo, Brazil
1218.22.1121 Boehringer Ingelheim Investigational Site
Tatui, Brazil
1218.22.1125 Boehringer Ingelheim Investigational Site
Uberlândia, Brazil
Bulgaria
1218.22.1207 Boehringer Ingelheim Investigational Site
Blagoevgrad, Bulgaria
1218.22.1210 Boehringer Ingelheim Investigational Site
Byala, Bulgaria
1218.22.1206 Boehringer Ingelheim Investigational Site
Kazanlak, Bulgaria
1218.22.1204 Boehringer Ingelheim Investigational Site
Plovdiv, Bulgaria
1218.22.1203 Boehringer Ingelheim Investigational Site
Ruse, Bulgaria
1218.22.1201 Boehringer Ingelheim Investigational Site
Sofia, Bulgaria
1218.22.1205 Boehringer Ingelheim Investigational Site
Sofia, Bulgaria
1218.22.1209 Boehringer Ingelheim Investigational Site
Sofia, Bulgaria
1218.22.1211 Boehringer Ingelheim Investigational Site
Sofia, Bulgaria
1218.22.1202 Boehringer Ingelheim Investigational Site
Varna, Bulgaria
Canada, Alberta
1218.22.1324 Boehringer Ingelheim Investigational Site
Edmonton, Alberta, Canada
1218.22.1330 Boehringer Ingelheim Investigational Site
Red Deer, Alberta, Canada
Canada, British Columbia
1218.22.1314 Boehringer Ingelheim Investigational Site
Burnaby, British Columbia, Canada
1218.22.1308 Boehringer Ingelheim Investigational Site
Penticton, British Columbia, Canada
1218.22.1307 Boehringer Ingelheim Investigational Site
Vancouver, British Columbia, Canada
1218.22.1305 Boehringer Ingelheim Investigational Site
Victoria, British Columbia, Canada
1218.22.1317 Boehringer Ingelheim Investigational Site
Victoria, British Columbia, Canada
1218.22.1319 Boehringer Ingelheim Investigational Site
Victoria, British Columbia, Canada
Canada, Manitoba
1218.22.1334 Boehringer Ingelheim Investigational Site
Winnipeg, Manitoba, Canada
Canada, Nova Scotia
1218.22.1331 Boehringer Ingelheim Investigational Site
Halifax, Nova Scotia, Canada
Canada, Ontario
1218.22.1309 Boehringer Ingelheim Investigational Site
Barrie, Ontario, Canada
1218.22.1304 Boehringer Ingelheim Investigational Site
Burlington, Ontario, Canada
1218.22.1312 Boehringer Ingelheim Investigational Site
Etobicoke, Ontario, Canada
1218.22.1310 Boehringer Ingelheim Investigational Site
Markham, Ontario, Canada
1218.22.1301 Boehringer Ingelheim Investigational Site
Newmarket, Ontario, Canada
1218.22.1315 Boehringer Ingelheim Investigational Site
Sudbury, Ontario, Canada
1218.22.1320 Boehringer Ingelheim Investigational Site
Sudbury, Ontario, Canada
1218.22.1327 Boehringer Ingelheim Investigational Site
Sudbury, Ontario, Canada
Canada, Quebec
1218.22.1323 Boehringer Ingelheim Investigational Site
Greenfield Park, Quebec, Canada
1218.22.1328 Boehringer Ingelheim Investigational Site
Laval, Quebec, Canada
1218.22.1329 Boehringer Ingelheim Investigational Site
Longueuil, Quebec, Canada
1218.22.1306 Boehringer Ingelheim Investigational Site
Montreal, Quebec, Canada
1218.22.1316 Boehringer Ingelheim Investigational Site
Montreal, Quebec, Canada
1218.22.1333 Boehringer Ingelheim Investigational Site
St-Jerome, Quebec, Canada
1218.22.1311 Boehringer Ingelheim Investigational Site
Ville Saint-Laurent, Quebec, Canada
Canada
1218.22.1313 Boehringer Ingelheim Investigational Site
Brossard, Canada
1218.22.1321 Boehringer Ingelheim Investigational Site
Quebec, Canada
1218.22.1332 Boehringer Ingelheim Investigational Site
Quebec, Canada
Chile
1218.22.3505 Boehringer Ingelheim Investigational Site
Punta Arenas, Chile
1218.22.3503 Boehringer Ingelheim Investigational Site
Santiago, Chile
1218.22.3506 Boehringer Ingelheim Investigational Site
Santiago, Chile
1218.22.3507 Boehringer Ingelheim Investigational Site
Santiago, Chile
1218.22.3508 Boehringer Ingelheim Investigational Site
Santiago, Chile
1218.22.3511 Boehringer Ingelheim Investigational Site
Santiago, Chile
1218.22.3512 Boehringer Ingelheim Investigational Site
Santiago, Chile
1218.22.3501 Boehringer Ingelheim Investigational Site
Valdivia, Chile
1218.22.3510 Boehringer Ingelheim Investigational Site
Viña del Mar, Chile
China
1218.22.1408 Boehringer Ingelheim Investigational Site
Beijing, China
1218.22.1411 Boehringer Ingelheim Investigational Site
Guangzhou, China
1218.22.1406 Boehringer Ingelheim Investigational Site
Guiyang, China
1218.22.1402 Boehringer Ingelheim Investigational Site
Hangzhou, China
1218.22.1422 Boehringer Ingelheim Investigational Site
Jinan, China
1218.22.1423 Boehringer Ingelheim Investigational Site
Jinan, China
1218.22.1405 Boehringer Ingelheim Investigational Site
Nanning, China
1218.22.1414 Boehringer Ingelheim Investigational Site
Shanghai, China
1218.22.1412 Boehringer Ingelheim Investigational Site
Xi'an, China
1218.22.1421 Boehringer Ingelheim Investigational Site
Yinchuan, China
Colombia
1218.22.3603 Boehringer Ingelheim Investigational Site
Armenia, Colombia
1218.22.3604 Boehringer Ingelheim Investigational Site
Armenia, Colombia
1218.22.3608 Boehringer Ingelheim Investigational Site
Barranquilla, Colombia
1218.22.3609 Boehringer Ingelheim Investigational Site
Barranquilla, Colombia
1218.22.3621 Boehringer Ingelheim Investigational Site
Barranquilla, Colombia
1218.22.3601 Boehringer Ingelheim Investigational Site
Bogota, Colombia
1218.22.3612 Boehringer Ingelheim Investigational Site
Bogota, Colombia
1218.22.3615 Boehringer Ingelheim Investigational Site
Bogota, Colombia
1218.22.3619 Boehringer Ingelheim Investigational Site
Bogota, Colombia
1218.22.3610 Boehringer Ingelheim Investigational Site
Cali, Colombia
1218.22.3611 Boehringer Ingelheim Investigational Site
Cali, Colombia
1218.22.3613 Boehringer Ingelheim Investigational Site
Espinal, Colombia
1218.22.3616 Boehringer Ingelheim Investigational Site
Floridablanca, Colombia
1218.22.3614 Boehringer Ingelheim Investigational Site
Medellin, Colombia
1218.22.3623 Boehringer Ingelheim Investigational Site
Medellin, Colombia
1218.22.3618 Boehringer Ingelheim Investigational Site
Pasto, Colombia
1218.22.3622 Boehringer Ingelheim Investigational Site
Zipaquirá, Colombia
Croatia
1218.22.1501 Boehringer Ingelheim Investigational Site
Karlovac, Croatia
1218.22.1508 Boehringer Ingelheim Investigational Site
Krapinske Toplice, Croatia
1218.22.1502 Boehringer Ingelheim Investigational Site
Slavonski Brod, Croatia
1218.22.1503 Boehringer Ingelheim Investigational Site
Varazdin, Croatia
1218.22.1504 Boehringer Ingelheim Investigational Site
Zadar, Croatia
1218.22.1505 Boehringer Ingelheim Investigational Site
Zagreb, Croatia
1218.22.1510 Boehringer Ingelheim Investigational Site
Zagreb, Croatia
Czech Republic
1218.22.1603 Boehringer Ingelheim Investigational Site
Brno, Czech Republic
1218.22.1617 Boehringer Ingelheim Investigational Site
Brno, Czech Republic
1218.22.1602 Boehringer Ingelheim Investigational Site
Bruntal, Czech Republic
1218.22.1618 Boehringer Ingelheim Investigational Site
Chocen, Czech Republic
1218.22.1605 Boehringer Ingelheim Investigational Site
Dolni Brezany, Czech Republic
1218.22.1606 Boehringer Ingelheim Investigational Site
Hodonin, Czech Republic
1218.22.1601 Boehringer Ingelheim Investigational Site
Jindrichuv Hradec, Czech Republic
1218.22.1610 Boehringer Ingelheim Investigational Site
Liberec, Czech Republic
1218.22.1614 Boehringer Ingelheim Investigational Site
Marianske Lazne, Czech Republic
1218.22.1620 Boehringer Ingelheim Investigational Site
Nachod, Czech Republic
1218.22.1619 Boehringer Ingelheim Investigational Site
Olomouc, Czech Republic
1218.22.1607 Boehringer Ingelheim Investigational Site
Praha 10, Czech Republic
1218.22.1613 Boehringer Ingelheim Investigational Site
Praha 10, Czech Republic
1218.22.1604 Boehringer Ingelheim Investigational Site
Praha 2, Czech Republic
1218.22.1609 Boehringer Ingelheim Investigational Site
Praha 4 - Krc, Czech Republic
1218.22.1612 Boehringer Ingelheim Investigational Site
Praha 4 - Krc, Czech Republic
1218.22.1621 Boehringer Ingelheim Investigational Site
Praha 8, Czech Republic
1218.22.1616 Boehringer Ingelheim Investigational Site
Slany, Czech Republic
1218.22.1608 Boehringer Ingelheim Investigational Site
Teplice, Czech Republic
Germany
1218.22.3715 Boehringer Ingelheim Investigational Site
Bad Homburg, Germany
1218.22.3719 Boehringer Ingelheim Investigational Site
Bad Homburg, Germany
1218.22.3706 Boehringer Ingelheim Investigational Site
Bad Kreuznach, Germany
1218.22.3714 Boehringer Ingelheim Investigational Site
Berlin, Germany
1218.22.3703 Boehringer Ingelheim Investigational Site
Dresden, Germany
1218.22.3712 Boehringer Ingelheim Investigational Site
Dresden, Germany
1218.22.3718 Boehringer Ingelheim Investigational Site
Frankfurt am Main, Germany
1218.22.3701 Boehringer Ingelheim Investigational Site
Frankfurt, Germany
1218.22.3710 Boehringer Ingelheim Investigational Site
Hohenmölsen, Germany
1218.22.3716 Boehringer Ingelheim Investigational Site
Leipzig, Germany
1218.22.3717 Boehringer Ingelheim Investigational Site
Leipzig, Germany
1218.22.3720 Boehringer Ingelheim Investigational Site
Wallerfing, Germany
Hungary
1218.22.1719 Boehringer Ingelheim Investigational Site
Baja, Hungary
1218.22.1715 Boehringer Ingelheim Investigational Site
Balassagyarmat, Hungary
1218.22.1706 Boehringer Ingelheim Investigational Site
Balatonfured, Hungary
1218.22.1701 Boehringer Ingelheim Investigational Site
Budapest, Hungary
1218.22.1702 Boehringer Ingelheim Investigational Site
Budapest, Hungary
1218.22.1708 Boehringer Ingelheim Investigational Site
Budapest, Hungary
1218.22.1709 Boehringer Ingelheim Investigational Site
Budapest, Hungary
1218.22.1711 Boehringer Ingelheim Investigational Site
Budapest, Hungary
1218.22.1714 Boehringer Ingelheim Investigational Site
Budapest, Hungary
1218.22.1717 Boehringer Ingelheim Investigational Site
Debrecen, Hungary
1218.22.1705 Boehringer Ingelheim Investigational Site
Eger, Hungary
1218.22.1712 Boehringer Ingelheim Investigational Site
Hodmezovasarhely, Hungary
1218.22.1722 Boehringer Ingelheim Investigational Site
Kaposvar, Hungary
1218.22.1704 Boehringer Ingelheim Investigational Site
Komarom, Hungary
1218.22.1720 Boehringer Ingelheim Investigational Site
Letavertes, Hungary
1218.22.1716 Boehringer Ingelheim Investigational Site
Miskolc, Hungary
1218.22.1718 Boehringer Ingelheim Investigational Site
Pecs, Hungary
1218.22.1721 Boehringer Ingelheim Investigational Site
Szeged, Hungary
1218.22.1710 Boehringer Ingelheim Investigational Site
Zalaegerszeg, Hungary
Israel
1218.22.1902 Boehringer Ingelheim Investigational Site
Afula, Israel
1218.22.1901 Boehringer Ingelheim Investigational Site
Haifa, Israel
1218.22.1908 Boehringer Ingelheim Investigational Site
Haifa, Israel
1218.22.1911 Boehringer Ingelheim Investigational Site
Herzliya, Israel
1218.22.1905 Boehringer Ingelheim Investigational Site
Holon, Israel
1218.22.1904 Boehringer Ingelheim Investigational Site
Jerusalem, Israel
1218.22.1906 Boehringer Ingelheim Investigational Site
Kfar-Saba, Israel
1218.22.1909 Boehringer Ingelheim Investigational Site
Nahariya, Israel
1218.22.1903 Boehringer Ingelheim Investigational Site
Safed, Israel
1218.22.1910 Boehringer Ingelheim Investigational Site
Tel Aviv, Israel
Japan
1218.22.2006 Boehringer Ingelheim Investigational Site
Iizuka-shi, Japan
1218.22.2007 Boehringer Ingelheim Investigational Site
Kawanishi-shi, Japan
1218.22.2010 Boehringer Ingelheim Investigational Site
Kawasaki-shi, Japan
1218.22.2003 Boehringer Ingelheim Investigational Site
Kitakyushu-shi, Japan
1218.22.2001 Boehringer Ingelheim Investigational Site
Matsudo-shi, Japan
1218.22.2009 Boehringer Ingelheim Investigational Site
Matsuyama-shi, Japan
1218.22.2005 Boehringer Ingelheim Investigational Site
Nagano-shi, Japan
1218.22.2008 Boehringer Ingelheim Investigational Site
Nagoya-shi, Japan
1218.22.2004 Boehringer Ingelheim Investigational Site
Sashima-gun, Japan
1218.22.2002 Boehringer Ingelheim Investigational Site
Takamatsu-shi, Japan
Korea, Republic of
1218.22.3307 Boehringer Ingelheim Investigational Site
Anyang-si, Korea, Republic of
1218.22.3306 Boehringer Ingelheim Investigational Site
Busan, Korea, Republic of
1218.22.3308 Boehringer Ingelheim Investigational Site
Busan, Korea, Republic of
1218.22.3310 Boehringer Ingelheim Investigational Site
Busan, Korea, Republic of
1218.22.3302 Boehringer Ingelheim Investigational Site
Goyang-si, Korea, Republic of
1218.22.3312 Boehringer Ingelheim Investigational Site
Incheon, Korea, Republic of
1218.22.3301 Boehringer Ingelheim Investigational Site
Seoul, Korea, Republic of
1218.22.3303 Boehringer Ingelheim Investigational Site
Seoul, Korea, Republic of
1218.22.3304 Boehringer Ingelheim Investigational Site
Seoul, Korea, Republic of
1218.22.3305 Boehringer Ingelheim Investigational Site
Seoul, Korea, Republic of
1218.22.3309 Boehringer Ingelheim Investigational Site
Seoul, Korea, Republic of
1218.22.3313 Boehringer Ingelheim Investigational Site
Suwon-si, Korea, Republic of
1218.22.3311 Boehringer Ingelheim Investigational Site
Wonju, Korea, Republic of
Malaysia
1218.22.2109 Boehringer Ingelheim Investigational Site
Alor Setar, Malaysia
1218.22.2101 Boehringer Ingelheim Investigational Site
Klang, Malaysia
1218.22.2110 Boehringer Ingelheim Investigational Site
Kuala Lumpur, Malaysia
1218.22.2108 Boehringer Ingelheim Investigational Site
Kuantan, Malaysia
1218.22.2111 Boehringer Ingelheim Investigational Site
Petaling Jaya, Malaysia
1218.22.2104 Boehringer Ingelheim Investigational Site
Pulau Pinang, Malaysia
1218.22.2106 Boehringer Ingelheim Investigational Site
Serdang, Malaysia
1218.22.2105 Boehringer Ingelheim Investigational Site
Seri Manjung, Malaysia
1218.22.2107 Boehringer Ingelheim Investigational Site
Taiping, Malaysia
1218.22.2103 Boehringer Ingelheim Investigational Site
Tampin, Malaysia
Mexico
1218.22.2216 Boehringer Ingelheim Investigational Site
Chihuahua, Mexico
1218.22.2206 Boehringer Ingelheim Investigational Site
Cuautitlan Izcalli, Mexico
1218.22.2215 Boehringer Ingelheim Investigational Site
Culiacan, Mexico
1218.22.2219 Boehringer Ingelheim Investigational Site
Guadalajara, Mexico
1218.22.2213 Boehringer Ingelheim Investigational Site
Merida, Mexico
1218.22.2217 Boehringer Ingelheim Investigational Site
Merida, Mexico
1218.22.2207 Boehringer Ingelheim Investigational Site
Mexico, Mexico
1218.22.2211 Boehringer Ingelheim Investigational Site
Mexico, Mexico
1218.22.2214 Boehringer Ingelheim Investigational Site
Mexico, Mexico
1218.22.2220 Boehringer Ingelheim Investigational Site
Mexico, Mexico
1218.22.2222 Boehringer Ingelheim Investigational Site
Mexico, Mexico
1218.22.2223 Boehringer Ingelheim Investigational Site
Mexico, Mexico
1218.22.2224 Boehringer Ingelheim Investigational Site
Mexico, Mexico
1218.22.2202 Boehringer Ingelheim Investigational Site
Monterrey, Mexico
1218.22.2205 Boehringer Ingelheim Investigational Site
Monterrey, Mexico
1218.22.2221 Boehringer Ingelheim Investigational Site
Monterrey, Mexico
1218.22.2209 Boehringer Ingelheim Investigational Site
Morelia, Mexico
1218.22.2218 Boehringer Ingelheim Investigational Site
Queretaro, Mexico
1218.22.2208 Boehringer Ingelheim Investigational Site
Tijuana, Mexico
1218.22.2201 Boehringer Ingelheim Investigational Site
Zapopan, Mexico
1218.22.2204 Boehringer Ingelheim Investigational Site
Zapopan, Mexico
Netherlands
1218.22.2313 Boehringer Ingelheim Investigational Site
Arnhem, Netherlands
1218.22.2303 Boehringer Ingelheim Investigational Site
Dordrecht, Netherlands
1218.22.2306 Boehringer Ingelheim Investigational Site
Groningen, Netherlands
1218.22.2311 Boehringer Ingelheim Investigational Site
Groningen, Netherlands
1218.22.2307 Boehringer Ingelheim Investigational Site
Hoogeveen, Netherlands
1218.22.2703 Boehringer Ingelheim Investigational Site
Kemerovo, Netherlands
1218.22.2308 Boehringer Ingelheim Investigational Site
Maastricht, Netherlands
1218.22.2301 Boehringer Ingelheim Investigational Site
Rotterdam, Netherlands
1218.22.2312 Boehringer Ingelheim Investigational Site
Utrecht, Netherlands
1218.22.2305 Boehringer Ingelheim Investigational Site
Waalwijk, Netherlands
1218.22.2304 Boehringer Ingelheim Investigational Site
Zutphen, Netherlands
Poland
1218.22.2521 Boehringer Ingelheim Investigational Site
Chorzow, Poland
1218.22.2507 Boehringer Ingelheim Investigational Site
Gdansk, Poland
1218.22.2520 Boehringer Ingelheim Investigational Site
Gdansk, Poland
1218.22.2526 Boehringer Ingelheim Investigational Site
Gdynia, Poland
1218.22.2512 Boehringer Ingelheim Investigational Site
Grodzisk Mazowiecki, Poland
1218.22.2530 Boehringer Ingelheim Investigational Site
Katowice, Poland
1218.22.2522 Boehringer Ingelheim Investigational Site
Kielce, Poland
1218.22.2513 Boehringer Ingelheim Investigational Site
Krakow, Poland
1218.22.2505 Boehringer Ingelheim Investigational Site
Lodz, Poland
1218.22.2517 Boehringer Ingelheim Investigational Site
Lodz, Poland
1218.22.2531 Boehringer Ingelheim Investigational Site
Lodz, Poland
1218.22.2510 Boehringer Ingelheim Investigational Site
Lublin, Poland
1218.22.2514 Boehringer Ingelheim Investigational Site
Lublin, Poland
1218.22.2524 Boehringer Ingelheim Investigational Site
Lublin, Poland
1218.22.2529 Boehringer Ingelheim Investigational Site
Nowy Duninow, Poland
1218.22.2501 Boehringer Ingelheim Investigational Site
Oswiecim, Poland
1218.22.2518 Boehringer Ingelheim Investigational Site
Parczew, Poland
1218.22.2503 Boehringer Ingelheim Investigational Site
Poznan, Poland
1218.22.2509 Boehringer Ingelheim Investigational Site
Poznan, Poland
1218.22.2502 Boehringer Ingelheim Investigational Site
Pulawy, Poland
1218.22.2519 Boehringer Ingelheim Investigational Site
Ruda Slaska, Poland
1218.22.2516 Boehringer Ingelheim Investigational Site
Rzeszow, Poland
1218.22.2527 Boehringer Ingelheim Investigational Site
Sochaczew, Poland
1218.22.2515 Boehringer Ingelheim Investigational Site
Sroda Wielkopolska, Poland
1218.22.2525 Boehringer Ingelheim Investigational Site
Staszow, Poland
1218.22.2506 Boehringer Ingelheim Investigational Site
Torun, Poland
1218.22.2511 Boehringer Ingelheim Investigational Site
Torun, Poland
1218.22.2528 Boehringer Ingelheim Investigational Site
Warsaw, Poland
1218.22.2532 Boehringer Ingelheim Investigational Site
Warszaw, Poland
1218.22.2508 Boehringer Ingelheim Investigational Site
Wroclaw, Poland
1218.22.2523 Boehringer Ingelheim Investigational Site
Zamosc, Poland
1218.22.2504 Boehringer Ingelheim Investigational Site
Zgierz, Poland
Portugal
1218.22.3105 Boehringer Ingelheim Investigational Site
Braga, Portugal
1218.22.3101 Boehringer Ingelheim Investigational Site
Coimbra, Portugal
1218.22.3103 Boehringer Ingelheim Investigational Site
Lisboa, Portugal
1218.22.3104 Boehringer Ingelheim Investigational Site
Lisboa, Portugal
1218.22.3106 Boehringer Ingelheim Investigational Site
Lisboa, Portugal
1218.22.3108 Boehringer Ingelheim Investigational Site
Porto, Portugal
1218.22.3107 Boehringer Ingelheim Investigational Site
V. N. Gaia, Portugal
Romania
1218.22.2611 Boehringer Ingelheim Investigational Site
Alba Iulia, Romania
1218.22.2604 Boehringer Ingelheim Investigational Site
Bucuresti, Romania
1218.22.2607 Boehringer Ingelheim Investigational Site
Bucuresti, Romania
1218.22.2610 Boehringer Ingelheim Investigational Site
Bucuresti, Romania
1218.22.2613 Boehringer Ingelheim Investigational Site
Bucuresti, Romania
1218.22.2616 Boehringer Ingelheim Investigational Site
Bucuresti, Romania
1218.22.2619 Boehringer Ingelheim Investigational Site
Bucuresti, Romania
1218.22.2620 Boehringer Ingelheim Investigational Site
Bucuresti, Romania
1218.22.2622 Boehringer Ingelheim Investigational Site
Bucuresti, Romania
1218.22.2614 Boehringer Ingelheim Investigational Site
Buzau, Romania
1218.22.2603 Boehringer Ingelheim Investigational Site
Galati, Romania
1218.22.2615 Boehringer Ingelheim Investigational Site
Iasi, Romania
1218.22.2617 Boehringer Ingelheim Investigational Site
Iasi, Romania
1218.22.2618 Boehringer Ingelheim Investigational Site
Iasi, Romania
1218.22.2605 Boehringer Ingelheim Investigational Site
Oradea, Romania
1218.22.2608 Boehringer Ingelheim Investigational Site
Oradea, Romania
1218.22.2621 Boehringer Ingelheim Investigational Site
Oradea, Romania
1218.22.2612 Boehringer Ingelheim Investigational Site
Ploiesti, Romania
1218.22.2609 Boehringer Ingelheim Investigational Site
Sibiu, Romania
1218.22.2601 Boehringer Ingelheim Investigational Site
Targu Mures, Romania
1218.22.2602 Boehringer Ingelheim Investigational Site
Targu Mures, Romania
1218.22.2606 Boehringer Ingelheim Investigational Site
Timisoara, Romania
Russian Federation
1218.22.2702 Boehringer Ingelheim Investigational Site
Barnaul, Russian Federation
1218.22.2715 Boehringer Ingelheim Investigational Site
Kemerovo, Russian Federation
1218.22.2710 Boehringer Ingelheim Investigational Site
Moscow, Russian Federation
1218.22.2711 Boehringer Ingelheim Investigational Site
Moscow, Russian Federation
1218.22.2712 Boehringer Ingelheim Investigational Site
Moscow, Russian Federation
1218.22.2713 Boehringer Ingelheim Investigational Site
Moscow, Russian Federation
1218.22.2716 Boehringer Ingelheim Investigational Site
Moscow, Russian Federation
1218.22.2701 Boehringer Ingelheim Investigational Site
Novosibirsk, Russian Federation
1218.22.2704 Boehringer Ingelheim Investigational Site
Novosibirsk, Russian Federation
1218.22.2719 Boehringer Ingelheim Investigational Site
Novosibirsk, Russian Federation
1218.22.2722 Boehringer Ingelheim Investigational Site
Novosibirsk, Russian Federation
1218.22.2725 Boehringer Ingelheim Investigational Site
Omsk, Russian Federation
1218.22.2717 Boehringer Ingelheim Investigational Site
Perm, Russian Federation
1218.22.2718 Boehringer Ingelheim Investigational Site
Ryazan, Russian Federation
1218.22.2705 Boehringer Ingelheim Investigational Site
Saint-Petersburg, Russian Federation
1218.22.2706 Boehringer Ingelheim Investigational Site
Saint-Petersburg, Russian Federation
1218.22.2707 Boehringer Ingelheim Investigational Site
Saint-Petersburg, Russian Federation
1218.22.2709 Boehringer Ingelheim Investigational Site
Saint-Petersburg, Russian Federation
1218.22.2720 Boehringer Ingelheim Investigational Site
Saint-Petersburg, Russian Federation
1218.22.2724 Boehringer Ingelheim Investigational Site
Saint-Petersburg, Russian Federation
1218.22.2721 Boehringer Ingelheim Investigational Site
Sestroretsk, Russian Federation
1218.22.2708 Boehringer Ingelheim Investigational Site
St. Petersburg, Russian Federation
1218.22.2714 Boehringer Ingelheim Investigational Site
Tomsk, Russian Federation
South Africa
1218.22.2804 Boehringer Ingelheim Investigational Site
Alberton, South Africa
1218.22.2821 Boehringer Ingelheim Investigational Site
Bloemfontein, South Africa
1218.22.2823 Boehringer Ingelheim Investigational Site
Bloemfontein, South Africa
1218.22.2805 Boehringer Ingelheim Investigational Site
Cape Town, South Africa
1218.22.2808 Boehringer Ingelheim Investigational Site
Cape Town, South Africa
1218.22.2809 Boehringer Ingelheim Investigational Site
Cape Town, South Africa
1218.22.2811 Boehringer Ingelheim Investigational Site
Cape Town, South Africa
1218.22.2812 Boehringer Ingelheim Investigational Site
Cape Town, South Africa
1218.22.2813 Boehringer Ingelheim Investigational Site
Cape Town, South Africa
1218.22.2816 Boehringer Ingelheim Investigational Site
Cape Town, South Africa
1218.22.2815 Boehringer Ingelheim Investigational Site
Durban, South Africa
1218.22.2824 Boehringer Ingelheim Investigational Site
Durban, South Africa
1218.22.2826 Boehringer Ingelheim Investigational Site
Durban, South Africa
1218.22.2807 Boehringer Ingelheim Investigational Site
Johannesburg, South Africa
1218.22.2820 Boehringer Ingelheim Investigational Site
Johannesburg, South Africa
1218.22.2827 Boehringer Ingelheim Investigational Site
Johannesburg, South Africa
1218.22.2819 Boehringer Ingelheim Investigational Site
Krugersdorp, South Africa
1218.22.2801 Boehringer Ingelheim Investigational Site
Pretoria, South Africa
1218.22.2802 Boehringer Ingelheim Investigational Site
Pretoria, South Africa
1218.22.2803 Boehringer Ingelheim Investigational Site
Pretoria, South Africa
1218.22.2806 Boehringer Ingelheim Investigational Site
Pretoria, South Africa
1218.22.2818 Boehringer Ingelheim Investigational Site
Pretoria, South Africa
1218.22.2825 Boehringer Ingelheim Investigational Site
Verulam, South Africa
1218.22.2810 Boehringer Ingelheim Investigational Site
Worcester, South Africa
Spain
1218.22.3015 Boehringer Ingelheim Investigational Site
Almeria, Spain
1218.22.3013 Boehringer Ingelheim Investigational Site
Alzira, Spain
1218.22.3012 Boehringer Ingelheim Investigational Site
Badalona, Spain
1218.22.3002 Boehringer Ingelheim Investigational Site
Barcelona, Spain
1218.22.3005 Boehringer Ingelheim Investigational Site
Barcelona, Spain
1218.22.3006 Boehringer Ingelheim Investigational Site
Barcelona, Spain
1218.22.3017 Boehringer Ingelheim Investigational Site
Centelles, Spain
1218.22.3014 Boehringer Ingelheim Investigational Site
Madrid, Spain
1218.22.3001 Boehringer Ingelheim Investigational Site
Malaga, Spain
1218.22.3008 Boehringer Ingelheim Investigational Site
Malaga, Spain
1218.22.3010 Boehringer Ingelheim Investigational Site
Segovia, Spain
1218.22.3003 Boehringer Ingelheim Investigational Site
Sevilla, Spain
1218.22.3007 Boehringer Ingelheim Investigational Site
Sevilla, Spain
1218.22.3009 Boehringer Ingelheim Investigational Site
Valencia, Spain
1218.22.3016 Boehringer Ingelheim Investigational Site
Valencia, Spain
1218.22.3018 Boehringer Ingelheim Investigational Site
Villamartin, Spain
Taiwan
1218.22.3401 Boehringer Ingelheim Investigational Site
Kaohsiung, Taiwan
1218.22.3405 Boehringer Ingelheim Investigational Site
Kaohsiung, Taiwan
1218.22.3409 Boehringer Ingelheim Investigational Site
New Taipei City, Taiwan
1218.22.3408 Boehringer Ingelheim Investigational Site
Taichung, Taiwan
1218.22.3410 Boehringer Ingelheim Investigational Site
Tainan, Taiwan
1218.22.3402 Boehringer Ingelheim Investigational Site
Taipei, Taiwan
1218.22.3403 Boehringer Ingelheim Investigational Site
Taipei, Taiwan
1218.22.3407 Boehringer Ingelheim Investigational Site
Taoyuan County, Taiwan
Ukraine
1218.22.3227 Boehringer Ingelheim Investigational Site
Chernivtsi, Ukraine
1218.22.3206 Boehringer Ingelheim Investigational Site
Dnipropetrovsk, Ukraine
1218.22.3223 Boehringer Ingelheim Investigational Site
Ivano-Frankivsk, Ukraine
1218.22.3232 Boehringer Ingelheim Investigational Site
Ivano-Frankivsk, Ukraine
1218.22.3203 Boehringer Ingelheim Investigational Site
Kharkiv, Ukraine
1218.22.3204 Boehringer Ingelheim Investigational Site
Kharkiv, Ukraine
1218.22.3210 Boehringer Ingelheim Investigational Site
Kharkiv, Ukraine
1218.22.3215 Boehringer Ingelheim Investigational Site
Kharkiv, Ukraine
1218.22.3201 Boehringer Ingelheim Investigational Site
Kyiv, Ukraine
1218.22.3205 Boehringer Ingelheim Investigational Site
Kyiv, Ukraine
1218.22.3209 Boehringer Ingelheim Investigational Site
Kyiv, Ukraine
1218.22.3212 Boehringer Ingelheim Investigational Site
Kyiv, Ukraine
1218.22.3217 Boehringer Ingelheim Investigational Site
Kyiv, Ukraine
1218.22.3225 Boehringer Ingelheim Investigational Site
Kyiv, Ukraine
1218.22.3226 Boehringer Ingelheim Investigational Site
Kyiv, Ukraine
1218.22.3229 Boehringer Ingelheim Investigational Site
Kyiv, Ukraine
1218.22.3221 Boehringer Ingelheim Investigational Site
Lviv, Ukraine
1218.22.3224 Boehringer Ingelheim Investigational Site
Lviv, Ukraine
1218.22.3202 Boehringer Ingelheim Investigational Site
Poltava, Ukraine
1218.22.3228 Boehringer Ingelheim Investigational Site
Sumy, Ukraine
1218.22.3207 Boehringer Ingelheim Investigational Site
Vinnytsia, Ukraine
1218.22.3222 Boehringer Ingelheim Investigational Site
Vinnytsia, Ukraine
1218.22.3230 Boehringer Ingelheim Investigational Site
Vinnytsia, Ukraine
1218.22.3231 Boehringer Ingelheim Investigational Site
Vinnytsia, Ukraine
United Kingdom
1218.22.2909 Boehringer Ingelheim Investigational Site
Airdrie, United Kingdom
1218.22.2908 Boehringer Ingelheim Investigational Site
Birmingham, United Kingdom
1218.22.2910 Boehringer Ingelheim Investigational Site
Bradford on Avon, United Kingdom
1218.22.2905 Boehringer Ingelheim Investigational Site
Chesterfield, United Kingdom
1218.22.2912 Boehringer Ingelheim Investigational Site
Dumfries, United Kingdom
1218.22.2906 Boehringer Ingelheim Investigational Site
Dundee, United Kingdom
1218.22.2902 Boehringer Ingelheim Investigational Site
Exeter, United Kingdom
1218.22.2913 Boehringer Ingelheim Investigational Site
Glasgow, United Kingdom
1218.22.2903 Boehringer Ingelheim Investigational Site
Leicester, United Kingdom
1218.22.2901 Boehringer Ingelheim Investigational Site
London, United Kingdom
1218.22.2904 Boehringer Ingelheim Investigational Site
Swansea, United Kingdom
1218.22.2907 Boehringer Ingelheim Investigational Site
Welwyn Garden City, United Kingdom
1218.22.2911 Boehringer Ingelheim Investigational Site
Wolverhampton, United Kingdom
Sponsors and Collaborators
Boehringer Ingelheim
Eli Lilly and Company
Investigators
Study Chair: Boehringer Ingelheim Boehringer Ingelheim
  More Information

Responsible Party: Boehringer Ingelheim
ClinicalTrials.gov Identifier: NCT01897532     History of Changes
Other Study ID Numbers: 1218.22  2011-004148-23 
Study First Received: July 9, 2013
Last Updated: September 20, 2016
Health Authority: Argentina: Admin Nacional de Medicamentos, Alimentos Tecnologia Medica
Brazil: National Health Surveillance Agency
Bulgaria: Bulgarian Drug Agency
Canada: Health Canada
Chile: Instituto de Salud Pública de Chile
China: China Food and Drug Administration (CFDA)
Croatia: Ministry of Health and Social Care
Czech Republic: State Institute for Drug Control
Hungary: National Institute of Pharmacy
Israel: Ministry of Health
Japan: Pharmaceuticals and Medical Devices Agency
Korea: Food and Drug Administration
Malaysia: Ministry of Health
Mexico: Federal Commission for Sanitary Risks Protection
Netherlands: Central Committee Research Involving Human Subjects
Poland: Registration Medicinal Product Medical Device Biocidal Product
Portugal: National Pharmacy and Medicines Institute
Romania: National Medicines Agency
Russia: Ministry of Health and Social Development Russian Federation
South Africa: Medicines Control Council
Spain: Spanish Agency of Medicines
Taiwan : Food and Drug Administration
Ukraine: Ministry of Health
United Kingdom: Medicines and Healthcare Products Regulatory Agency
United States: Food and Drug Administration
Colombia: INVIMA Instituto Nacional de Vigilancia de Medicamentos y Alimentos
Germany: Federal Institute for Drugs and Medical Devices

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Linagliptin
Hypoglycemic Agents
Physiological Effects of Drugs
Incretins
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Dipeptidyl-Peptidase IV Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on September 27, 2016